(E28) FRENCKEN - SG
Sector: Technology | Industry: Scientific & Technical Instruments | Exchange: SG (Singapore) | Market Cap: 1.325m SGD | Total Return: 169.1% in 12m
Avg Turnover: 17.7M
Warnings
No concerns identified
Tailwinds
Rs Leader, Idiosyncratic Leader, Tailwind, Pullback 52w, Avwap Ph Week
Frencken Group Limited is a Singapore-based investment holding company that specializes in original design manufacturing (ODM) and original equipment manufacturing (OEM). The firm operates primarily through two segments: Mechatronics and Integrated Manufacturing Services (IMS). The Mechatronics division focuses on precision-engineered systems for high-tech industries including semiconductors, medical imaging, and aerospace, while the IMS division provides contract design and manufacturing for the automotive and office automation sectors.
The company utilizes a diversified manufacturing footprint across Europe and Asia to mitigate regional supply chain risks. In the precision engineering sector, business models often rely on deep technical integration with customers, creating high switching costs due to the specialized nature of modular assembly and system integration. Investors can explore more detailed valuation metrics for this stock at ValueRay.
Frenckens capabilities extend to specialized services such as vacuum coating, thermal management products, and plastic injection molding. By serving cyclical industries like semiconductors alongside more defensive sectors like medical and analytical instrumentation, the company maintains a balanced exposure to global capital expenditure trends.
- Semiconductor equipment demand recovery drives Mechatronics segment revenue growth
- Margin expansion hinges on higher capacity utilization in European facilities
- Automotive sector weakness pressures Integrated Manufacturing Services segment profitability
- Capital expenditure cycles of global lithography and medical OEMs dictate valuation
| Net Income: 39.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 7.96 > 1.0 |
| NWC/Revenue: 38.03% < 20% (prev 36.37%; Δ 1.67% < -1%) |
| CFO/TA 0.23 > 3% & CFO 166.7m > Net Income 39.1m |
| Net Debt (-94.1m) to EBITDA (79.5m): -1.18 < 3 |
| Current Ratio: 2.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (427.1m) vs 12m ago 0.02% < -2% |
| Gross Margin: 14.26% > 18% (prev 14.52%; Δ -0.26% > 0.5%) |
| Asset Turnover: 117.3% > 50% (prev 108.1%; Δ 9.22% > 0%) |
| Interest Coverage Ratio: 8.97 > 6 (EBIT TTM 48.0m / Interest Expense TTM 5.35m) |
| A: 0.44 (Total Current Assets 524.3m - Total Current Liabilities 195.3m) / Total Assets 740.2m |
| B: 0.50 (Retained Earnings 367.1m / Total Assets 740.2m) |
| C: 0.07 (EBIT TTM 48.0m / Avg Total Assets 737.7m) |
| D: 1.82 (Book Value of Equity 475.3m / Total Liabilities 261.4m) |
| Altman-Z'' = 6.88 = AAA |
| DSRI: 0.93 (Receivables 138.9m/137.8m, Revenue 865.1m/794.3m) |
| GMI: 1.02 (GM 14.52% / 14.26%) |
| AQI: 1.06 (AQ_t 0.04 / AQ_t-1 0.04) |
| SGI: 1.09 (Revenue 865.1m / 794.3m) |
| TATA: -0.17 (NI 39.1m - CFO 166.7m) / TA 740.2m) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of June 16, 2026, the stock is trading at SGD 3.09 with a total of 6,980,600 shares traded.
Over the past week, the price has changed by +6.19%,
over one month by -2.83%,
over three months by +56.07% and
over the past year by +169.09%.
FRENCKEN has no consensus analysts rating.
P/E Trailing = 34.3333
P/E Forward = 27.4725
P/S = 1.5315
P/B = 2.5531
P/EG = 2.1634
Revenue TTM = 865.1m SGD
EBIT TTM = 48.0m SGD
EBITDA TTM = 79.5m SGD
Long Term Debt = 585k SGD (from longTermDebt, last quarter)
Short Term Debt = 21.7m SGD (from shortLongTermDebt, last quarter)
Debt = 67.8m SGD (Leases only: 67.8m)
Net Debt = -94.1m SGD (calculated: Debt 67.8m - CCE 161.9m)
Enterprise Value = 1.23b SGD (1.32b + Debt 67.8m - CCE 161.9m)
Interest Coverage Ratio = 8.97 (Ebit TTM 48.0m / Interest Expense TTM 5.35m)
EV/FCF = 8.37x (Enterprise Value 1.23b / FCF TTM 147.0m)
FCF Yield = 11.95% (FCF TTM 147.0m / Enterprise Value 1.23b)
FCF Margin = 17.00% (FCF TTM 147.0m / Revenue TTM 865.1m)
Net Margin = 4.52% (Net Income TTM 39.1m / Revenue TTM 865.1m)
Gross Margin = 14.26% ((Revenue TTM 865.1m - Cost of Revenue TTM 741.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.66 (Enterprise Value 1.23b / Total Assets 740.2m)
Interest Expense / Debt = 7.90% (Interest Expense 5.35m / Debt 67.8m)
Taxrate = 20.41% (10.1m / 49.4m)
NOPAT = 38.2m (EBIT 48.0m * (1 - 20.41%))
Current Ratio = 2.68 (Total Current Assets 524.3m / Total Current Liabilities 195.3m)
Debt / Equity = 0.14 (Debt 67.8m / totalStockholderEquity, last quarter 475.3m)
Debt / EBITDA = -1.18 (Net Debt -94.1m / EBITDA 79.5m)
Debt / FCF = -0.64 (Net Debt -94.1m / FCF TTM 147.0m)
Total Stockholder Equity = 440.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.30% (Net Income 39.1m / Total Assets 740.2m)
RoE = 8.87% (Net Income TTM 39.1m / Total Stockholder Equity 440.9m)
RoCE = 10.87% (EBIT 48.0m / Capital Employed (Equity 440.9m + L.T.Debt 585k))
RoIC = 7.61% (NOPAT 38.2m / Invested Capital 501.7m)
WACC = 10.04% (E(1.32b)/V(1.39b) * Re(10.23%) + D(67.8m)/V(1.39b) * Rd(7.90%) * (1-Tc(0.20)))
Discount Rate = 10.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 78.11 | Cagr: 0.06%
[DCF] Terminal Value 72.71% ; FCFF base≈123.2m ; Y1≈141.3m ; Y5≈207.9m
[DCF] Fair Price = 5.84 (EV 2.41b - Net Debt -94.1m = Equity 2.50b / Shares 428.8m; r=10.04% [WACC]; 5y FCF grow 15.0% → 2.50% )
Revenue Correlation: 99.76 | Revenue CAGR: 7.92% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=0.10 | Chg30d=-1.16% | Revisions=-43% | GrowthEPS=+11.9% | GrowthRev=+5.1%
EPS next Year (2027-12-31): EPS=0.12 | Chg30d=+1.20% | Revisions=+14% | GrowthEPS=+15.5% | GrowthRev=+7.7%
[Analyst] Revisions Ratio: -43%